跳至主要内容
临床试验/EUCTR2008-000132-40-CZ
EUCTR2008-000132-40-CZ进行中(未招募)不适用

Efficacy of AM 111 in Patients with Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study

Auris Medical AG0 个研究点目标入组 204 人开始时间: 2010年12月30日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
204

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients with unilateral acute sensorineural hearing loss (ASNHL) with onset 48 hours or less ago
  • Mean hearing loss compared with the unaffected contralateral ear* of at least 30 dB in the 3 most affected contiguous frequencies
  • Age = 18 years and = 60 years
  • Negative pregnancy test for women of childbearing potential
  • Able to attend the on-study visits
  • Written informed consent before participation in the study
  • * For patients with asymmetric hearing or bilateral ASNHL resulting from acoustic trauma (most affected ear is treated), hearing loss is determined against a pre-existing audiogram (not older than 3 years), or, if no pre-existing audiogram is available, age- and sex-adjusted normative values according to ISO 7029:2000 (Statistical distribution of hearing thresholds as a function of age adjusting for the age-related hearing loss”).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Bilateral ASNHL, if not resulting from acoustic trauma
  • Suspected perilymph fistula or membrane rupture
  • Barotrauma
  • Average air bone gap higher than 20 dB in 3 contiguous frequencies
  • History of Meniere disease, autoimmune hearing loss, radiation-induced hearing loss, endolymphatic hydrops, suspected retro-cochlear lesion or fluctuating hearing loss
  • Previous ASNHL incident within the past 6 weeks
  • Evidence of acute or chronic otitis media or otitis externa on examination
  • Any drug-based therapy for inner ear hearing loss that is ongoing or was performed in the past 2 weeks
  • Any therapy known as ototoxic (e.g. aminoglycosides, cisplatin, loop diuretics, quinine etc.) in the past 6 months prior to study inclusion

研究者

相似试验